focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,126.00
Bid: 12,124.00
Ask: 12,128.00
Change: -46.00 (-0.38%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-Dollar firms as U.S. yields tick up ahead of Fed guidance

Wed, 17th Mar 2021 08:50

* Dollar firm after three days of gains ahead of Fed
* Fed 2023 rates projections under scrutiny
* Euro may be hampered by delay in vaccine rollouts
* Graphic: World FX rates https://tmsnrt.rs/2RBWI5E

(Adds comment; updates prices)
By Julien Ponthus
LONDON, March 17 (Reuters) - The U.S. dollar firmed on
Wednesday with 10-year Treasury yields close to 13-month highs
ahead of a Federal Reserve policy meeting which could shed some
light on the timing of future rate hikes and the central bank’s
tolerance for rising yields.
With Fed policymakers expected to forecast the fastest U.S.
economic growth in decades in the wake of COVID-19 vaccinations
and $1.9 trillion in new stimulus, market participants will be
focused on clues that the central bank could start raising rates
in 2023, earlier than it had said.
In any event, expectations of a faster-than-expected
economic recovery will likely weigh.
"U.S. yields might receive further upwards thrust and pull
the dollar along with them in the absence of a clear commitment
on the part of the Fed that a further rise in yields is
undesirable", Commerzbank Antje Praefcke analyst wrote in a
morning note.
She added that because the European Central Bank had in
contrast committed to increase the pace of bond buying to keep a
lid on rising yields, the euro might suffer against the dollar
in the short term.
The euro was down 0.07% at $1.1893 after declining in
the past three sessions.
Hurt by a possible delay in the European Union's vaccination
effort, the euro seemed set to test last week's 3 1/2-month low
of $1.18355.
Europe's medicines watchdog will release results of its
investigation into incidents of bleeding, blood clots and low
platelet counts in recipients of AstraZeneca's
coronavirus vaccine on Thursday afternoon.
Europe's painful recovery from the pandemic is in sharp
contrast with other economies which seem less dependant on
monetary stimulus to pull though.
The Bank of Canada for instance is likely to reduce its bond
purchases as soon as next month, strategists say.
In morning trades in Europe, the dollar index ticked up
0.09% and stood at 91.953, having already risen for three
straight sessions on support mainly from elevated U.S. bond
yields.
Benchmark 10-year Treasury yields were also
ticking up at 1.6340%. They had reached 1.6420% on Friday for
the first time since February 2020.
Against the yen, the greenback firmed 0.15% to 109.14 yen
, hovering near nine-month highs hit this week.
The British pound was up 0.14% at $1.3914 recovering
from profit-taking after it hit a near three-year high last
month on the back of a fast vaccine rollout.
Commodity-linked currencies including the Australian dollar
, the New Zealand dollar and the Canadian dollar
eased slightly against the U.S. dollar, tracking weakness
in commodity prices.
In the cryptocurrency market, bitcoin fell 2.1%
to $55,708.79, slipping further away from a record high of
$61,781.83 hit on Saturday.

========================================================
Currency bid prices at 843 GMT
Description RIC Last U.S. Close Pct Change YTD Pct High Bid Low Bid
Previous Change
Session
Euro/Dollar $1.1894 $1.1903 -0.08% -2.66% +1.1908 +1.1887
Dollar/Yen 109.1250 109.0200 +0.12% +5.67% +109.2000 +109.0950
Euro/Yen 129.80 129.75 +0.04% +2.25% +129.9300 +129.7200
Dollar/Swiss 0.9279 0.9248 +0.34% +4.89% +0.9280 +0.9248
Sterling/Dollar 1.3914 1.3895 +0.14% +1.85% +1.3929 +1.3880
Dollar/Canadian 1.2461 1.2448 +0.10% -2.14% +1.2462 +1.2434
Aussie/Dollar 0.7729 0.7746 -0.19% +0.49% +0.7747 +0.7724
NZ Dollar/Dollar 0.7182 0.7190 -0.11% +0.01% +0.7194 +0.7174


All spots
Tokyo spots
Europe spots
Volatilities
Tokyo Forex market info from BOJ


(Reporting by Hideyuki Sano in Tokyo and Sagarika Jaisinghani
in Bengaluru; Editing by Sam Holmes, Gerry Doyle and Andrew
Cawthorne)

More News
Today 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.